Sara Furbo

Ms. Sara Furbo

Center for Surgical Science
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in APMIS
Verified
Journal Article
Open access
PDF file
ABAstrid L. B. Bennedsen
Astrid L. B. Bennedsen
SFSara Furbo
Sara Furbo
TBThomas Bjarnsholt
Thomas Bjarnsholt
HRHans Henrik Raskov
Hans Henrik Raskov
Ismail GögenurIsmail Gögenur
Ismail Gögenur
Lasse Andersson KvichLasse Andersson Kvich
Lasse Andersson Kvich
Current evidence suggests that bacteria contribute to the development of certain cancers, such as colorectal cancer (CRC), partly by stimulating chronic inflammation. However, little is known about the bacterial impact on molecular pathways in CRC. Recent studies have demonstrated how specific bacteria can influence the major CRC‐related pathways, i.e., Wnt, PI3K‐Akt, MAPK, TGF‐β, EGFR, mTOR, and p53. In order to advance the current understanding and facilitate the choice of pathways to investigate, we have systematically collected and summarized the current knowledge within bacterial altered major pathways in CRC. Several pro‐tumorigenic and anti‐tumorigenic bacterial species and their respective metabolites interfere with the major signaling pathways addressed in this review. Not surprisingly, some of these studies investigated known CRC drivers, such as Escherichia coli, Fusobacterium nucleatum, and Bacteroides fragilis. Interestingly, some metabolites produced by bacterial species typically considered pathogenic, e.g., Vibrio cholera, displayed anti‐tumorigenic activities, emphasizing the caution needed when classifying healthy and unhealthy microorganisms. The results collectively emphasize the complexity of the relationship between the microbiota and the tumorigenesis of CRC, and future studies should verify these findings in more realistic models, such as organoids, which constitute a promising platform. Moreover, future trials should investigate the clinical potential of preventive modulation of the gut microbiota regarding CRC development.

20 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SFSara Furbo
Sara Furbo
PUPaulo César Martins Urbano
Paulo César Martins Urbano
HRHans Raskov
Hans Raskov
JTJesper T. Troelsen
Jesper T. Troelsen
AFAnne-Marie Kanstrup Kanstrup Fiehn
Anne-Marie Kanstrup Kanstrup Fiehn
Ismail GögenurIsmail Gögenur
Ismail Gögenur
Surgical resection is the mainstay in intended curative treatment of colorectal cancer (CRC) and may be accompanied by adjuvant chemotherapy. However, 40% of the patients experience recurrence within five years of treatment, highlighting the importance of improved, personalized treatment options. Monolayer cell cultures and murine models, which are generally used to study the biology of CRC, are associated with certain drawbacks; hence, the use of organoids has been emerging. Organoids obtained from tumors display similar genotypic and phenotypic characteristics, making them ideal for investigating individualized treatment strategies and for integration as a core platform to be used in prediction models. Here, we review studies correlating the clinical response in patients with CRC with the therapeutic response in patient-derived organoids (PDO), as well as the limitations and potentials of this model. The studies outlined in this review reported strong associations between treatment responses in the PDO model and clinical treatment responses. However, as PDOs lack the tumor microenvironment, they do not genuinely account for certain crucial characteristics that influence therapeutic response. To this end, we reviewed studies investigating PDOs co-cultured with tumor-infiltrating lymphocytes. This model is a promising method allowing evaluation of patient-specific tumors and selection of personalized therapies. Standardized methodologies must be implemented to reach a “gold standard” for validating the use of this model in larger cohorts of patients. The introduction of this approach to a clinical scenario directing neoadjuvant treatment and in other curative and palliative treatment strategies holds incredible potential for improving personalized treatment and its outcomes.

1 September 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MBMalene Broholm
Malene Broholm
TDThea Helene Degett
Thea Helene Degett
SFSara Furbo
Sara Furbo
AFAnne-Marie Kanstrup Fiehn
Anne-Marie Kanstrup Fiehn
MBMustafa Bulut
Mustafa Bulut
IGIsmail Gögenur
Ismail Gögenur